United States regulator approves Roche’s Covid-19 antibody test
Through a blood sample, the test can detect antibodies to the new coronavirus, which could signal a person may have already been infected.
Copyright 2020 The Associated Press. All Rights Reserved.
The US Food and Drug Administration (FDA) has given emergency approval for use of the serological test developed by Swiss pharmaceutical giant Roche, the company announced on Sunday.
The test is designed to determine whether a person has been exposed to the new coronavirus and developed antibodies against the disease.
The Basel-based firm says that its Elecsys Anti-SARS-CoV-2 test has a specificity rate of 99.8% – which lowers the chance of false positives – and detects antibodies with 100% sensitivity.
Roche has started shipping the new test to laboratories around the world and says it plans to increase production to “high dougle-digit millions per month” to supply countries that accept the CE mark as well as the US.
Scientists worldwide are in a race to develop serological tests, as results can help policy-makers better understand the disease, determine who may have had the virus and who may have immunity, and what measures may still be needed to fight the pandemic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Ex-sect member sentenced in Zurich for sexual abuse
This content was published on
Zurich District Court has sentenced a former member of the globally active sect "Children of God" to a partial prison sentence.
SNB chairman does not rule out slowdown in Swiss growth
This content was published on
Martin Schlegel, chairman of the Swiss National Bank (SNB), does not rule out a weakening of the Swiss economy in light of the tariff dispute.
Swiss NGOs abroad to receive 10% less federal funding
This content was published on
In 2025 and 2026, Swiss NGOs will have 10% less federal funding available for international cooperation than in the previous two-year period.
Swiss parties spent less than CHF1 million on February green vote
This content was published on
Swiss political parties spent CHF 700,000 ($840,000) on campaigns in the run-up to the overwhelmingly defeated vote on February 9, according to the Swiss Federal Audit Office.
This content was published on
Swisswool, the largest Swiss wool processor, is not accepting any wool for the first time this spring. For many sheep farmers, the only option is to get rid of the wool.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
What Swiss researchers are doing to beat Covid-19
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
This test could help Switzerland get back on track
This content was published on
While we await a vaccine or treatment, scientists are developing tests to tell us how widespread the virus is, such as the serological test.
Covid-19 immunity testing to begin in some Swiss hospitals
This content was published on
The hospitals are planning to roll out testing to evaluate how many people have already been infected, including those who may have already be immune.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.